Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Oct 08, 2021
Application for quotation of securities - NEU
Oct 06, 2021
Update - Proposed issue of securities - NEU
Oct 06, 2021
$3.3 million raised from oversubscribed SPP
Oct 01, 2021
Feedback on Angelman IND and submission of Pitt Hopkins IND
Sep 21, 2021
IND application submitted for NNZ-2591 in Phelan-McDermid
Sep 17, 2021
Share Purchase Plan Offer Booklet
Sep 16, 2021
Section 708A Notice
Sep 16, 2021
New patent issued to 2032 for Neuren's trofinetide in Brazil
Sep 16, 2021
Application for quotation of securities - NEU
Sep 13, 2021
Investor Presentation, 13 September 2021
Previous
1
2
3
4
5
6
Next
